Biden’s Agenda livePolitics Updates Taxing the Rich $ 4 Trillion Economic Plan Biden’s Approval Rating Advertisement Continue reading the main story Supported by Continue reading the main story Buoyed by Federal Covid Aid, Big Hospital Chains Buy Up Competitors The pandemic barely dented the financial outlook for some major networks, which continued to acquire weaker… Read More »
BASKING RIDGE, N.J. and SHIRLEY, N.Y., May 6, 2021 /PRNewswire/ — Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer® (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult… Read More »
Prior to the COVID-19 public health crisis, there was momentum to transform operating rooms into digitally connected environments to allow surgeons to collaborate and medical device companies to share best practices and products. Social distancing mandates over the past year accelerated those efforts as virtual reality and remote training technologies have been widely adopted. The value… Read More »
FDA Approves Zynrelef (bupivacaine and meloxicam) for the Management of Postoperative Pain SAN DIEGO, May 13, 2021 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food… Read More »
FDA Approves Empaveli (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved Empaveli™ (pegcetacoplan), the first and only targeted C3 therapy… Read More »